Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhima Qianzi Capsules for bortezomib-induced peripheral neuropathy in multiple myeloma (self-controlled, phase 4)
ChiCTR2200058869Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nux vomica in multiple myeloma (MM) and peripheral neuropathy, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: TCM symptom score, Neurotoxicity score and 1 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
nux vomica
03
Conditions
multiple myeloma (MM)peripheral neuropathy
Beyond the preview
Go deeper on ChiCTR2200058869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058869.